New combo therapy aims to tackle breast cancer brain metastases
NCT ID NCT04923542
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether combining a targeted drug (abemaciclib) with precise radiation (stereotactic radiosurgery) can better control brain tumors in people with a common type of breast cancer (HR+/HER2-). About 31 participants will receive both treatments along with hormone therapy. The main goal is to see how long the brain tumors stay under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Abemaciclib (Verzenio) and stereotactic radiosurgery
What this could lead to
If successful, this combination could offer a new way to control brain metastases in HR+/HER2- breast cancer, potentially delaying progression and improving outcomes.
What could go wrong
This is an early-phase, single-arm study with only 31 participants, so results may not apply broadly. Side effects from the drug or radiation could be significant, and the treatment may not improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
ACTIVE_NOT_RECRUITINGTampa, Florida, 33612, United States
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact